Keros Therapeutics halts two dosing arms of cibotercept Phase 2 trial due to pericardial effusion safety concerns; continues ...
Illumina exec Vik Vaz as CEO to advance biological detection tech for drug research. The company uses what it calls ...
Corcept Therapeutics' dazucorilant fails Phase 2 ALS trial after missing primary endpoint, following October's Cushing's ...
Lonza CEO Wolfgang Wienand plans to exit capsules/health ingredients market and restructure into three business units, with ...
New drugs in the US were, on average, approved months before winning approval in the EU, according to new data from The IQVIA ...
Another trial for SIGA Technologies' mpox antiviral has failed, and all enrollment has been stopped, the NIH's National ...
Candel Therapeutics’ viral immunotherapy candidate passed a late-stage test in certain patients with prostate cancer, sending ...
UnitedHealthcare CEO Brian Thompson's shooting death sparked public discussion about healthcare industry frustration. The ...
Relay Therapeutics’ stock {$RLAY} rose about 6% on Wednesday morning after it released positive interim data for its PI3Kα ...
Companies Beam Therapeutics and Prime Medicines presented research on reducing chemotherapy in gene therapy conditioning, ...
Ace­lyrin is of­fi­cial­ly end­ing de­vel­op­ment of an ex­per­i­men­tal med­i­cine it re­ferred to as a “ di­a­mond in the ...
Through a new relationship with Eli Lilly, Ro patients can now get easier access to the drugmaker’s discounted, single-dose ...